AbbVie's 64th-Highest Volume Stock Tangles with Icotyde Threat as Earnings Beat and Dividend Strength Offset Generic Pressures

Market Snapshot

On March 24, 2026, AbbVie’s (ABBV) stock closed with a 0.13% gain, trading at a volume of $1.43 billion, which placed it at the 64th highest trading volume among stocks on the day. Despite this modest positive movement, the stock remains under pressure from broader competitive and market dynamics. The company’s best-selling drug, Skyrizi (an injectable IL-23 inhibitor), faces a significant challenge from Johnson & Johnson’s (JNJ) newly FDA-approved oral IL-23 inhibitor, Icotyde, which has raised concerns about market share erosion.

Key Drivers

The recent FDA approval of JNJ’s Icotyde represents a critical competitive threat to AbbVie’s Skyrizi, a product that generated $17.6 billion in sales in 2025. Icotyde’s oral administration format is seen as a superior patient convenience compared to Skyrizi’s injectable delivery, prompting analysts to highlight the potential for significant revenue displacement. The market reacted sharply to this development, with AbbVie’s stock dropping approximately 5% in the days following the approval—a decline that erased $28 billion in market capitalization. This regulatory milestone also triggered a $50 million milestone payment to Protagonist Therapeutics (PTGX), a key collaborator in Icotyde’s development, and created speculative interest in a potential acquisition of PTGX by JNJ, further amplifying competitive tensions.

AbbVie’s recent strategic moves to bolster its pipeline, however, have provided some countervailing support. The company announced a multi-year collaboration with Alloy Therapeutics to enhance its antibody discovery capabilities in immunology, aiming to reduce reliance on existing blockbusters. Additionally, AbbVie reported strong quarterly earnings, exceeding estimates with $2.71 per share and raising FY2026 guidance to $14.37–$14.57. The firm also maintained its robust dividend policy, declaring a $1.73 quarterly payout (3.4% yield), which has historically attracted income-focused investors. These fundamentals have contributed to a “Moderate Buy” average analyst rating, though divergent opinions persist, with some firms like Citigroup lowering price targets while others, such as Piper Sandler, raised theirs to $299.

Competitive pressures extend beyond Icotyde. AbbVie faces generic erosion of older products, such as Savella, which now faces a generic equivalent from Breckenridge. This has added modest but cumulative revenue risks in its pain management segment. Institutional investors, however, have shown continued confidence: Procyon Advisors LLC increased its stake by 19.9% in Q4 2025, and several other firms acquired new positions in Q2–Q3 2026. Despite this, insider sales by executives like EVP Perry Siatis and SVP David Purdue have raised questions about internal sentiment, though their combined ownership remains relatively small at 0.25% of the company.

Analyst sentiment remains mixed, reflecting uncertainty about AbbVie’s ability to navigate these challenges. While some firms like BMO Capital Markets and Berenberg Bank maintain “Outperform” or “Overweight” ratings, others, including Evercore and Citigroup, have tempered expectations with lower price targets. The stock’s recent underperformance against peers and broader market volatility has also amplified investor caution, with short-term price action reflecting a re-pricing of growth assumptions for Skyrizi and the company’s near-term outlook.

In summary, AbbVie’s stock performance is shaped by a tug-of-war between strong fundamentals—such as earnings beats, dividend stability, and pipeline investments—and headwinds from competitive threats like Icotyde and generic pressures. While the company’s strategic collaborations and robust cash flow position it for long-term resilience, near-term volatility is likely to persist as the market weighs the balance of these factors.